Equity

BHSRX

Health Sciences Opportunities Fund

Overview

Loading

Performance

Performance

Growth of Hypothetical $10,000

Performance chart data not available for display.
View full chart

Distributions

Interactive chart displaying fund performance. Javascript is required.

View full chart
  1y 3y 5y 10y
26.60 14.56 13.33 16.55
Benchmark (%) 24.60 12.42 12.61 16.07
Morningstar Category Avg. (%) 23.51 11.82 9.42 14.88
Morningstar Ranking 91/141 24/122 21/114 -
Morningstar Quartile 3 1 1 2
Lipper Category Avg. (%) 32.36 11.25 10.97 15.88
Lipper Ranking 67/108 22/92 19/83 -
Lipper Quartile 3 1 1 -
  YTD 1m 3m 1y 3y 5y 10y
10.24 -0.83 6.26 26.60 50.37 86.96 362.57
Benchmark (%) 8.41 -1.28 6.48 24.60 42.07 81.11 343.93
Morningstar Category Avg. (%) 9.68 -1.54 0.95 23.51 39.80 56.82 300.26
Lipper Category Avg. (%) 11.34 0.54 5.13 32.36 38.49 70.94 345.79
  2015 2016 2017 2018 2019
Total Return (%) 10.69 -6.37 24.41 7.63 24.89
Benchmark (%) 7.14 -3.33 23.13 5.63 22.11
Morningstar Category Avg. (%) 8.05 -10.60 24.31 -0.40 26.23
The performance quoted represents past performance and does not guarantee future results. Investment return and principal value of an investment will fluctuate so that an investor's shares, when sold or redeemed, may be worth more or less than the original cost. Current performance may be lower or higher than the performance quoted. The performance information for periods prior to the inception date of the share class are based on the Fund’s Investor A Shares, adjusted to reflect the fees and expenses applicable to such share class. See the fund prospectus for more details.

Key Facts

Key Facts

Size of Class (Millions) as of Nov 27, 2020 $263.6 M
Size of Fund (Millions) as of Nov 27, 2020 $10,046.8 M
Share Class launch date Sep 12, 2011
Asset Class Equity
Morningstar Category Health
Lipper Classification Health/Biotech Funds
Benchmark Index Russell 3000 HealthCare Index
CUSIP 091936815
Distribution Frequency None
Number of Holdings as of Oct 30, 2020 132
Max Offer Price as of Nov 27, 2020 $71.35
Open to New Investors Yes
Turnover Percent in the Annual Report as of Jun 30, 2020 41%

Portfolio Characteristics

Portfolio Characteristics

P/B Ratio as of Oct 30, 2020 4.71
P/E Ratio - Forward as of Oct 30, 2020 20.18
Average Market Cap (Millions) as of Oct 30, 2020 $ 102,923.6 M
Best 3-Month Return Over the Last 3 Years 3 months ending Jun 30, 2020 17.38%
Worst 3-Month Return Over the Last 3 Years 3 months ending Mar 31, 2020 -11.62%
Fund Standard Deviation (3y) as of Oct 31, 2020 15.86
Active Share as of Oct 30, 2020 39.91%

This information must be preceded or accompanied by a current prospectus. For standardized performance, please see the Performance section above.

Fees

Fees

as of current prospectus
Gross Expense Ratio 1.46%
Net Expense Ratio 1.46%

Net Expense Ratio excluding Investment Related Expenses is 1.45%

  • Acquired Fund Fees and Expenses 0.01%
  • Interest expense 0.00%

Ratings

Ratings

Morningstar Rating

4
Overall Morningstar Rating for Health Sciences Opportunities Fund, Class R, as of Oct 31, 2020 rated against 133 Health Funds based on risk adjusted total return.

Lipper Leader

 
 
 
 
Overall Lipper Leaders ratings based on an equal-weighted average of percentile ranks for each measure over 3-, 5-, and 10-year periods (if applicable) and do not take into account the effects of sales charges for these categories (Consistent Return, Preservation, Total Return, Expense, and Tax Efficiency) as of Oct 31, 2020 out of 92, 12,117, 92, 49 and 92 Funds, respectively in Lipper's Health/Biotech Funds classification.

Holdings

Holdings

as of Oct 30, 2020
Name Weight (%)
UNITEDHEALTH GROUP INC 7.00
ABBOTT LABORATORIES 5.26
JOHNSON & JOHNSON 4.30
THERMO FISHER SCIENTIFIC INC 3.73
MEDTRONIC PLC 2.75
Name Weight (%)
BOSTON SCIENTIFIC CORPORATION 2.64
HUMANA INC 2.55
AMGEN INC 2.51
STRYKER CORPORATION 2.47
ELI LILLY AND COMPANY 2.42

Exposure Breakdowns

Exposure Breakdowns

as of Oct 30, 2020

% of Market Value

Type Fund Benchmark Net
as of Oct 30, 2020

% of Market Value

Type Fund Benchmark Net
as of Oct 30, 2020

% of Market Value

Type Fund Benchmark Net
as of Oct 30, 2020

% of Market Value

Type Fund Benchmark Net
Negative weightings may result from specific circumstances (including timing differences between trade and settle dates of securities purchased by the funds) and/or the use of certain financial instruments, including derivatives, which may be used to gain or reduce market exposure and/or risk management.

Allocations are subject to change.

Portfolio Managers

Portfolio Managers

Erin Xie
Head of the Health Sciences team
Xiang Liu
BlackRock Health Sciences Team
Jeffrey Lee
BlackRock Health Sciences Team
Portfolio Manager

Literature

Literature

 

There are many ways to access BlackRock Funds, learn how you can add them to your portfolio